Drug Trial Radar · NCT06120491
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,898
Actual
Start
Nov 21, 2023
Primary completion
Sep 30, 2027
Study completion Apr 30, 2031
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Conditions
- Metastatic Castration-Sensitive Prostate Cancer
Interventions
SaruparibDrug
Oral
PlaceboDrug
Oral
Abiraterone AcetateDrug
Oral
DarolutamideDrug
Oral
EnzalutamideDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic Progression-Free Survival (rPFS)Time frame: Up to approximately 50 months
Locations
322 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Chandler, Arizona
Research Site
Gilbert, Arizona
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
Little Rock, Arkansas
Research Site
Springdale, Arkansas
Research Site
Bakersfield, California
Research Site
Fountain Valley, California
Research Site
Fullerton, California
Research Site
Los Angeles, California
Research Site
Montebello, California
Research Site
San Francisco, California
Research Site
Santa Barbara, California
Research Site
Santa Monica, California
Research Site
Santa Rosa, California
Research Site
Golden, Colorado
Research Site
Lakewood, Colorado
Research Site
New Haven, Connecticut
Research Site
Atlanta, Georgia
Research Site
Glenview, Illinois
Research Site
Lake Barrington, Illinois
Research Site
Fort Wayne, Indiana
Research Site
Indianapolis, Indiana
Research Site
Westwood, Kansas
Research Site
Shreveport, Louisiana
Research Site
Scarborough, Maine
Research Site
Baltimore, Maryland
Research Site
Baltimore, Maryland
Research Site
Bethesda, Maryland
Research Site
Towson, Maryland
Research Site
Upper Marlboro, Maryland
Research Site
Grand Rapids, Michigan
Research Site
Troy, Michigan
Research Site
Rochester, Minnesota
Research Site
Bozeman, Montana
Research Site
Las Vegas, Nevada
Research Site
Las Vegas, Nevada
Research Site
Camden, New Jersey
Research Site
Albuquerque, New Mexico
Research Site
East Syracuse, New York
Showing 40 of 322 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.